HIV associated nephropathy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 21: | Line 21: | ||
of patients with HIVAN have a [[CD4]] count of less than 200. HIVAN presents with [[nephrotic syndrome]] and progressive [[renal failure]]. Despite being a cause of chronic renal failure kidney sizes are usually normal or large. | of patients with HIVAN have a [[CD4]] count of less than 200. HIVAN presents with [[nephrotic syndrome]] and progressive [[renal failure]]. Despite being a cause of chronic renal failure kidney sizes are usually normal or large. | ||
==Incidence== | |||
Much more common in Black and African American patients with [[HIV]]. In the USA 12% of patients dying with [[AIDS]] have histologically proven HIVAN, the worldwide incidence amongst [[AIDS]] patients appears to be similar. A South African study at [[Tygerberg Hospital]], [[Stellenbosch University]], has shown HIVAN histology in 33/61(54%) [[biopsies]] performed in HIV positive patients. | Much more common in Black and African American patients with [[HIV]]. In the USA 12% of patients dying with [[AIDS]] have histologically proven HIVAN, the worldwide incidence amongst [[AIDS]] patients appears to be similar. A South African study at [[Tygerberg Hospital]], [[Stellenbosch University]], has shown HIVAN histology in 33/61(54%) [[biopsies]] performed in HIV positive patients. | ||
Among black adults in the USA it is the third most common cause of ESRF. | Among black adults in the USA it is the third most common cause of ESRF. | ||
==Pathology== | |||
Involves all components of the [[nephron]]. Typical findings are that of collapsing [[FSGS]] (Focal segmental glomerulosclerosis)and mycrocystic tubular dilatation. | Involves all components of the [[nephron]]. Typical findings are that of collapsing [[FSGS]] (Focal segmental glomerulosclerosis)and mycrocystic tubular dilatation. | ||
==Treatment== | |||
There is as yet inadeqaute data from randomised controlled trials. | There is as yet inadeqaute data from randomised controlled trials. | ||
Revision as of 20:47, 17 February 2012
| HIV associated nephropathy |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
HIV-Associated Nephropathy (HIVAN) is a type of collapsing FSGS. Serious renal complication of advanced HIV infection and AIDS leading to chronic and eventually end stage renal failure(ESRF). HIVAN is caused by direct infection of the renal cells with the HIV-1 virus and leads to renal damage through the viral gene products. It could also be caused by changes in the release of cytokines during HIV infection.
Usually occurs only in advanced disease and approximately 80% of patients with HIVAN have a CD4 count of less than 200. HIVAN presents with nephrotic syndrome and progressive renal failure. Despite being a cause of chronic renal failure kidney sizes are usually normal or large.
Incidence
Much more common in Black and African American patients with HIV. In the USA 12% of patients dying with AIDS have histologically proven HIVAN, the worldwide incidence amongst AIDS patients appears to be similar. A South African study at Tygerberg Hospital, Stellenbosch University, has shown HIVAN histology in 33/61(54%) biopsies performed in HIV positive patients.
Among black adults in the USA it is the third most common cause of ESRF.
Pathology
Involves all components of the nephron. Typical findings are that of collapsing FSGS (Focal segmental glomerulosclerosis)and mycrocystic tubular dilatation.
Treatment
There is as yet inadeqaute data from randomised controlled trials.
Treatment with HAART and ACE inhibitors/Angiotensin receptor blockers has been shown to be beneficial and should be given to all patients unless otherwise contra-indicated. General renoprotective measures and the treatment of the complications of nephrotic syndrome and renal failure are adjunctive.
Corticosteroid treatment can be useful in patients who do not respond to the above treatment. There is some evidence that cyclophosphamide might be helpful in selective cases, however further trials are required on both steroids and cyclophosphamide before these drugs can become standardised treatmen if at all.